Bicara Therapeutics Inc. beat EPS estimates 29% of the time across 7 reported quarters (2 beats, 5 misses), averaging -22.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.77 | $-0.82 | -6.5% | Miss | Q2 FY26 call · transcript |
| Q1 FY26 | $-0.64 | $-0.93 | -45.3% | Miss | |
| Q4 FY25 | $-0.72 | $-0.68 | +5.6% | Beat | Q4 FY25 call · transcript |
| Q3 FY25 | $-0.55 | $-0.67 | -21.8% | Miss | |
| Q2 FY25 | $-0.54 | $-0.50 | +7.4% | Beat | |
| Q1 FY25 | $-0.40 | $-0.68 | -70.0% | Miss | |
| Q4 FY24 | $-0.31 | $-0.39 | -25.8% | Miss | |
| Q3 FY24 | not reported | $-1.60 | not reported | not reported |
Back to BCAX overview · BCAX holders · BCAX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.